Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 6Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 23Gastrointestinal 8Endocrine 8Sarcoma 7Thoracic 5Head & Neck 5NET 4Gynecologic 3Dermatologic 2CNS 2Breast 2Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1HIV Infections 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Medullary 1

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × cabozantinib × Breast × Clear all
NCT04514484 2026-05-28

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled 32 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

Phase 1 Active not recruiting
914 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡